Rethinking MASH: Integrating Systemic Risk with Liver-Centered Disease Mechanisms

MASLD arises within systemic metabolic dysfunction, but what determines progression to MASH and fibrosis within the liver? This program examines how hepatic metabolic adaptation can become maladaptive under persistent stress, triggering cellular injury, inflammatory signaling, and fibrogenesis that drive progressive liver disease. Industry Supporter: Madrigal Pharmaceuticals Inc.